Research Insights

In the rapidly evolving landscape of structural biology and AI-native drug discovery, the frontier is moving faster than ever. Almost weekly, new computational models are released, each claiming to outperform previous benchmarks on critical macromolecular structure prediction tasks. For a lean, mission-driven startup like AlgorithmicRx, this explosion of open-science tools is a massive equalizer. But it also introduces a critical scientific question: How do we separate model-

At AlgorithmicRx, our mission has always been clear: accelerate the discovery of transformative therapies for rare diseases by combining deep biology with artificial intelligence. As our platform advances into the MVP stage, we are continuing to refine not only how we identify therapeutic targets, but also how we build biological confidence around them before moving into downstream drug design. Beyond Target Discovery Our AI platform integrates diverse biological data—includi

The AlgorithmicRx team participated virtually in July 29's U.S. Food and Drug Administration (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting reviewing Capricor Therapeutics' Biologics License Application (BLA) for Deramiocel as a potential treatment for Duchenne muscular dystrophy (DMD). Following presentations from FDA reviewers, Capricor Therapeutics, scientific experts, physicians, patients, caregivers, and advocacy organizations, the Advisor

We're building a computational proof-of-concept (POC) that uses AlphaFold 3 to discover compensatory proteins capable of restoring a critical structural link broken in DMD: from disease hypothesis to in silico validation The Problem Duchenne Muscular Dystrophy (DMD) is caused by mutations in the dystrophin gene , that leave the protein truncated or missing entirely. Dystrophin normally acts as a molecular shock absorber, anchoring the cell's internal actin skeleton to the...